We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy of Helicobater pylori eradication in patients with diffuse large B‐cell lymphoma of the stomach: A systematic review.
- Authors
De Francesco, Vincenzo; Manta, Raffaele; Marmo, Riccardo; Marmo, Clelia; Rago, Angela; Antonelli, Giulio; Hassan, Cesare; Zullo, Angelo
- Abstract
Objectives: The role of Helicobater pylori eradication in the treatment of high‐grade diffuse large B‐cell lymphoma (DLBCL) of the stomach is unclear. Methods: We performed a systematic review and meta‐analysis of currently available data. DLBCL‐remission rate after eradication therapy, post‐remission maintenance, and response rate in the case of additional oncological therapy were extracted. Results: By considering data of seven studies, the DLBCL remission was achieved in 81 (53.3%; 95% CI = 45.3–61.2) out of 152 H. pylori eradicated patients. The regression rate did not differ between pure DLCBL and DLCBL with MALT component, between stage I and stage II disease, and between Caucasians and Asians. Disease regression was maintained in all patients after at a median of 63 months (range: 46–29) follow‐up. In those non‐responders, DLBLC remission after additional chemo‐immunotherapy was achieved in 63 (98.4%; 95% CI = 95.4–100) out of 64 patients. Conclusions: Data this systematic review suggest considering H. pylori eradication as first‐line therapy to treat infected patients with early‐stage, high‐grade gastric lymphoma.
- Subjects
DIFFUSE large B-cell lymphomas; HELICOBACTER pylori infections; STOMACH; HELICOBACTER pylori
- Publication
European Journal of Haematology, 2022, Vol 109, Issue 6, p643
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.13871